关于Bcl-2凋亡蛋白家族的研究进展

正常细胞变成癌细胞的过程中经历了一系列的遗传和表观遗传变化,其中B细胞淋巴瘤/白血病-2(B cell lymphoma/leukemia-2,Bcl-2)在众多的肿瘤细胞中都有高表达,高表达的Bcl-2能形成凋亡抵抗而使癌细胞对化疗产生耐药性,从而使化疗药失去效用。由此可见,针对这些变化的治疗手段可能对肿瘤以及耐药肿瘤有治疗效果。在过去的30年里,无数研究者通过对Bcl-2调控的凋亡通路的研究,促进了一系列拮抗Bcl-2蛋白的小分子化合物的发展。本文就对Bcl-2蛋白的发现、研究、家族情况以及在肿瘤发生发展和治疗中的作用做综述。

A set of genetic and epigenetic alterations are the mark of tumor formation,and Bcl-2 （B cell lymphoma/leukemia-2,the Bcl-2） has high expression in numerous tumor cells,high expression of Bcl-2 can form apoptosis resistance and make the cancer cells develop resistance to chemotherapy. It follows that therapies designed to counter these alterations might be effective as anti-cancer strategies.In the past 30 years,numbers of researchers has promoted the development of small-molecule compounds to against the Bcl-2 protein.This article focuses on the discovery and study of BCL-2,the wider BCL-2 protein family and,specifically,its roles in cancer development and therapy.